2021—2023年天津市安定医院第二类精神药品使用情况分析

目的 通过对天津市安定医院2021—2023年第二类精神药品的使用情况进行分析，为临床上加强精神药品管理、合理用药提供参考。方法 通过提取2021年1月—2023年12月天津市安定医院第二类精神药品的相关信息，对其销售金额、销售量、药物使用频度（DDDs）、药物日均费用（DDC）、药物排序比（B/A）进行回顾性统计分析。结果 天津市安定医院第二类精神药品销售金额和DDDs逐年增长，艾司唑仑片的DDDs始终位于第1位；第二类精神药品的DDC值总体上较为稳定，个别品种出现上涨。奥沙西泮片、扎来普隆片、咪达唑仑片的DDC值排序始终位于前3位；艾司唑仑片、阿普唑仑片等药物的B/A大于1，地西泮注射液、地西泮片的B/A接近于1，咪达唑仑片、扎来普隆片、酒石酸唑吡坦片等药物的B/A小于1，咪达唑仑注射液的B/A等于1。结论 天津市安定医院第二类精神药品的使用基本合理，建议以国家三级公立医院绩效考核为抓手，多措并举优化各项药事管理措施，进一步提升合理用药的精细化管理水平。

Analysis of the use of the second type of psychotropic drugs in Tianjin Anding Hospital from 2021 to 2023

Objective To analyze the use of second type of psychotropic drugs in Tianjin Anding Hospital from 2021 to 2023, and provide reference for strengthening the management of psychotropic drugs and rational drug use in clinical practice. Method By extracting relevant information on second type of psychotropic drugs from Tianjin Anding Hospital from January 2021 to December 2023, a retrospective statistical analysis was conducted on their sales amount, sales volume, DDDs, DDC, and B/A. Results The consumption sum and DDDs of the second type of psychotropic drugs in Tianjin Anding Hospital increased year by year, and the DDDs of Estazolam Tablets always ranked first. The DDC value of the second type of psychotropic drugs was generally stable, and some varieties showed an increase. The DDC values of Oxazepam Tablets, Zaleplon Tablets, and Midazolam Tablets were always ranked in the top 3. The B/A of Estazolam Tablets, Alprazolam Tablets, and other drugs is greater than 1, that of Diazepam Injection and DiazepamTablets is close to 1, that of Midazolam Tablets, Zaleplon Tablets, Zolpidem Tartrate Tablets and other drugs is less than 1, that of Midazolam Injection is equal to 1. Conclusion The use of second type of psychotropic drugs in Tianjin Anding Hospital is basically reasonable. It is recommended to use the performance evaluation of national tertiary public hospitals as a starting point, take multiple measures to optimize various pharmaceutical management measures, and improve the level of refined management of rational drug use.